Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

39.77 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,050
Open	39.77
Bid (Size)	39.28 (300)
Ask (Size)	39.99 (100)
Prev. Close	39.77
Today's Range	39.77 - 39.77
52wk Range	32.63 - 90.32
Shares Outstanding	8,168,788
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SLNO

Today 8:00 EDT

From DJS Law Group

Via Business Wire

Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

March 09, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Performance

YTD	-15.7%	-15.7%
1 Month	-2.7%	-2.7%
3 Month	-22.3%	-22.3%
6 Month	-45.0%	-45.0%
1 Year	-9.0%	-9.0%

More News

Securities Fraud Investigation Into Soleno Therapeutics, Inc. (SLNO) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

March 09, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

Soleno Therapeutics (NASDAQ:SLNO) Beats Q4 2025 Estimates Amid Cautious Market Reaction to VYKAT XR Launch ↗

February 25, 2026

Via Chartmill

Kaplan Fox Encourages Investors of Soleno Therapeutics, Inc. (SLNO) to Contact the Firm Before Lead Plaintiff Deadline on May 5, 2026

March 09, 2026

Via NewMediaWire

Kaplan Fox Encourages Investors of Soleno Therapeutics, Inc. (SLNO) to Contact the Firm Before Lead Plaintiff Deadline on May 5, 2026

March 09, 2026

Via TheNewswire.com

Securities Fraud Investigation Into Soleno Therapeutics, Inc. (SLNO) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

March 09, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

SOLENO LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. and Encourages Investors to Contact the Firm

March 09, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 09, 2026

From The Schall Law Firm

Via Business Wire

SLNO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026

March 09, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

Rosen Law Firm Urges Soleno Therapeutics, Inc. (NASDAQ: SLNO) Stockholders to Contact the Firm for Information About Their Rights

March 09, 2026

From Rosen Law Firm

Via Business Wire

INVESTOR NOTICE: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit filed by Robbins Geller Rudman & Dowd LLP

March 09, 2026

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

March 06, 2026

From Robbins LLP

Via Business Wire

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗

February 27, 2026

Via Stocktwits

Soleno (SLNO) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

SLNO INVESTOR ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Fraud Investigation

January 16, 2026

From Kirby McInerney LLP

Via GlobeNewswire

SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc.

January 12, 2026

From Kirby McInerney LLP

Via Business Wire

SLNO Investigation: Investors Encouraged to Contact Kirby McInerney LLP

January 09, 2026

From Kirby McInerney LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Encourages Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations

January 08, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

Soleno Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (SLNO)

December 30, 2025

From Kirby McInerney LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

Via MarketMinute

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗

December 03, 2025

Via The Motley Fool

Bragar Eagel & Squire, P.C. Encourages Agilon, Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations

December 03, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Frequently Asked Questions

Is Soleno Therapeutics, Inc. - Common Stock publicly traded?

Yes, Soleno Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Soleno Therapeutics, Inc. - Common Stock trade on?

Soleno Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Soleno Therapeutics, Inc. - Common Stock?

The ticker symbol for Soleno Therapeutics, Inc. - Common Stock is SLNO on the Nasdaq Stock Market

What is the current price of Soleno Therapeutics, Inc. - Common Stock?

The current price of Soleno Therapeutics, Inc. - Common Stock is 39.77

When was Soleno Therapeutics, Inc. - Common Stock last traded?

The last trade of Soleno Therapeutics, Inc. - Common Stock was at 03/09/26 04:00 PM ET

What is the market capitalization of Soleno Therapeutics, Inc. - Common Stock?

The market capitalization of Soleno Therapeutics, Inc. - Common Stock is 324.87M

How many shares of Soleno Therapeutics, Inc. - Common Stock are outstanding?

Soleno Therapeutics, Inc. - Common Stock has 325M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.